Shares of Adamis Pharmaceuticals Corp. (ADMP) - Get Report rose 5.2% to $6.05 in premarket trading on Friday, June 16, on the heels of the San Diego firm's June 15 announcement that it has secured U.S. Food and Drug Administration approval for its epinephrine pre-filled syringe for treating allergic reactions like anaphylaxis. The agency has also approved the trade name of Symjepi.
Shares of Mylan N.V. (MYL) - Get Report , maker of the EpiPen and target of Washington scrutiny due to dramatic price increases in its allergy treatment, fell 14 cents to $36.82 in early trading Friday due to the prospect of added competition.
Meanwhile, shares of Impax Laboratories Inc. (IPXL) were up 4.7% to $14.50. Cantor Fitzgerald & Co. analyst Louise Chen on June 15 began coverage of the Hayward, Calif.-based firm with an overweight rating and a $20 price target.
"We think the new CEO, Paul Bisaro, can help transform Impax from a mid-size generics company into a leading generics and specialty pharma company," Chen wrote. "Therefore, we expect upward earnings revisions to drive Impax's stock higher."
Worried about how to pay for your golden years? Ken Fisher, founder of Fisher Investments, and TheStreet's Jim Cramer will tell you what you need to know in a June 21 webinar on the market trends that are shaping retirement planning today. Register here for the event, which starts at 11 a.m. ET.